Get better Answers
With Innovative, Adaptive Clinical Trials.
Berry is a scientific consulting company specializing in innovative adaptive clinical trial design, Bayesian analysis, implementation, and software solutions for the pharmaceutical and medical device industry.
To seek efficient answers for new medical advancements, you need more. That’s why Berry offers innovative statisticians and software for the freedom to design and implement adaptive clinical trials. Get the answers you need from analysis to approval and beyond.
Innovative Trials, Better Outcomes.
Berry has extensive experience in the design, implementation, and software solutions of adaptive clinical trials across many medical disciplines. Adaptive trials can result in better insights, greater efficiency, better treatment for participants in a trial, and better information for regulators and the medical community. Here’s the Adaptive Trial Process.
Adaptive Clinical Trial Design
Allow the pre-specification of flexible components to the major aspects of a trial, like the treatment arms, the allocation to the different treatment arms, the patient population, and the sample size.
Trial Implementation
Our services include interim and final analyses for primary and key secondary efficacy endpoints, providing expert guidance on best practices for adaptive design implementation, and interacting with Data Safety Monitoring Boards (DSMB) for adaptive and platform trials.
Clinical Trial Software
Software solutions that help Biostatisticians rapidly design, compare, and simulate both fixed and adaptive trial designs through powerful, versatile and fast simulation tools.
Platform Trials
Innovative clinical trials that evaluate multiple treatments simultaneously and intended to continue beyond the evaluation of any one treatment, while maximizing statistical and clinical efficiency.
Latest News and Events
75: Mammograms: Death Threats, Hillary Clinton and Lead-Time Bias
In this episode of "In the Interim…", Dr. Don Berry provides a detailed account of co-chairing the 1997 NIH consensus development conference on mammography for women in their 40s.
74: REMAP-CAP Results: Oseltamivir in Critically-Ill Influenza Patients
In this episode of "In the Interim…", Dr. Scott Berry speaks with Dr. Srinivas Murthy, Dr. Thomas Hills, and Dr. Lindsay Berry about the REMAP-CAP trial results on oseltamivir in critically ill influenza patients.
73: ICECAP: The Results
In this episode of "In the Interim…", Dr. Scott Berry leads a comprehensive discussion of the ICECAP trial results with four Principal Investigators.
72: Failure of the Proportional Odds is the Result
In this episode of "In the Interim…", Dr. Scott Berry and Dr. Elizabeth Lorenzi systematically examine the analytic pitfalls in recent acute ischemic stroke trials, especially the implications of violating the proportional odds assumption on the modified Rankin Scale.
71: Adaptive Design Actions Matrix
In this episode of "In the Interim…", Dr. Scott Berry challenges the widely held belief that any interim look at trial data obligates an alpha adjustment.
70: A Visit with Tim Berry
In this episode of "In the Interim…," Dr. Scott Berry interviews Tim Berry, co-founder of Blend360, detailing a career that demonstrates the practical application of statistical and analytical methods within large-scale business environments.
69: Fairness in Soccer and Clinical Trials
In this episode of "In the Interim...", Dr. Scott Berry investigates the practical meaning of fairness by connecting a controversial World Cup soccer ruling to foundational questions in clinical trial statistics.
Latest Publications
We’re continually refining and reshaping the clinical trials for the betterment of our clients and their patients.
